A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of KDX-0811(Dexrazoxane) in the treatment of accidental extravasation of anthracycline anti-cancer agents.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Antineoplastic Agents; Dexrazoxane; Razoxane

Criteria

Inclusion Criteria:

• Patients suspected to have been exposed to extravasation of anthracycline

Exclusion Criteria:

• Patients reasonably suspected to have been exposed to extravasation by other compounds than anthracyclines through the same IV access, e.g. vincristine, mitomycin, and vinorelbine, all of which may cause ulceration